<DOC>
	<DOCNO>NCT01230892</DOCNO>
	<brief_summary>Nebivolol novel blood pressure lower drug additional effect inner line blood vessel release compound call nitric oxide relax blood vessel . Atenolol blood pressure reduce agent without ability release nitric oxide effect additional blood vessel relaxation . The goal proposal compare Nebivolol Atenolol respect follow parameter : - Plaque within artery supply heart term volume composition assess ultrasound within artery . - Ability small artery heart open deliver enhance blood supply response drug call Adenosine ( routinely use cardiac catheterization laboratory ) assess pressure flow detect catheter within artery . - Ability inner line artery supply heart release relax compound call nitric oxide response injection Acetylcholine ( also use cardiac catheterization laboratory ) assess squirt dye artery - Local force affect blood flow artery supply heart assess superimpose data complex map create offline Georgia Institute Technology . It likely Nebivolol cause plaque within artery supply heart change 'vulnerable ' type 'stable ' type plaque . There several feature `` vulnerable plaque '' detect artery heart use intravascular ultrasound ( small ultrasound camera go artery heart ) . The investigator hypothesis Nebivolol prove superior Atenolol reduce 'vulnerable plaque ' , improve blood flow within small artery health inner line artery 1 year time point . The investigator plan enroll 20 patient study ( 26 patient include dropout ) randomize 1:1 manner Nebivolol Vs Atenolol 1 year repeat evaluation time point .</brief_summary>
	<brief_title>Evaluation The Effects Nebivolol Comparison Atenolol Wall Shear Stress Rupture Prone Coronary Plaques</brief_title>
	<detailed_description>Primary hypothesis : Nebivolol therapy reduce number thin-cap fibroatheromas , VH-IVUS define `` vulnerable plaque '' compare Atenolol patient undergo serial angiography IVUS . Secondary Hypotheses : - Nebivolol therapy improve coronary microvascular function - Nebivolol therapy improve coronary endothelial function - Nebivolol therapy improve coronary wall shear stress Specific Aims : To evaluate , patient stable angina acute coronary syndrome moderate angiographic coronary artery disease , effect Nebivolol 5 mg day compare Atenolol 50 mg day : - The number thin cap fibroatheromas , percent necrotic core , percent atheroma volume define novel Virtual Histology IVUS ( VHâ„¢ IVUS ) . - The coronary shear stress profile measure use 3 dimensional vessel reconstruction , flow velocity measurement , computational fluid dynamic . - Microvascular function determine coronary flow reserve fractional flow reserve measure invasive Doppler/pressure assessment . - Endothelial function determine response quantitative coronary angiography Doppler assessment intracoronary acetylcholine challenge .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Rupture</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Patients stable angina acute coronary syndrome Moderate coronary lesion ( defined lesion significant enough treating physician warrant evaluation use CFR FFR intravascular ultrasound assessment ) . Lesion locate proximal 60mm RCA LAD . On stable medical therapy cardiac risk factor . Left Main lesion great 50 % stenosis Patients history coronary artery bypass surgery Severe valvular heart disease Patients present STEMI . Inability provide inform consent prior randomization Creatinine &gt; 1.5 Lesions locate beyond 60mm epicardial vessel Coronary anatomy require CABG Bblocker , calcium channel blocker extendedrelease nitrate therapy within last 48 hour . Bradycardia ( HR &lt; 50 bpm ) Hypotension ( SBP &lt; 100mmHg ) Severe COPD pulmonary function test</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>